Inflammation and clearance of Chlamydia trachomatis in enteric and nonenteric mucosae.
Immunization(s) fostering the induction of genital mucosa-targeted immune effectors is the goal of vaccines against sexually transmitted diseases. However, it is uncertain whether vaccine administration should be based on the current assumptions about the common mucosal immune system. We investigated the relationship between mucosal sites of infection, infection-induced inflammation, and immune-mediated bacterial clearance in mice using the epitheliotropic pathogen Chlamydia trachomatis. Chlamydial infection of the conjunctival, pulmonary, or genital mucosae stimulated significant changes in tissue architecture with dramatic up-regulation of the vascular addressin, VCAM, a vigorous mixed-cell inflammatory response with an influx of alpha4beta1+ T cells, and clearance of bacteria within 30 days. Conversely, intestinal mucosa infection was physiologically inapparent, with no change in expression of the local MAdCAM addressin, no VCAM induction, no histologically detectable inflammation, and no tissue pathology. Microbial clearance was complete within 60 days in the small intestine but bacterial titers remained at high levels for at least 8 months in the large intestine. These findings are compatible with the notion that VCAM plays a functional role in recruiting cells to inflammatory foci, and its absence from the intestinal mucosa contributes to immunologic homeostasis at that site. Also, expression of type 1 T cell-mediated immunity to intracellular Chlamydia may exhibit tissue-specific variation, with the rate and possibly the mechanism(s) of clearance differing between enteric and nonenteric mucosae. The implications of these data for the common mucosal immune system and the delivery of vaccines against mucosal pathogens are discussed.
Igietseme
J U
JU
Department of Microbiology and Immunology, Morehouse School of Medicine, Atlanta, Georgia 30310, USA. igietsj@msm.edu
Portis
J L
JL
Perry
L L
LL
D000818:Animals; D000954:Antigens, Surface / Q000302:isolation & purification; D001402:B-Lymphocytes / Q000276:immunology; D015815:Cell Adhesion Molecules / Q000302:isolation & purification; D002690:Chlamydia Infections / Q000276:immunology*; D002692:Chlamydia trachomatis / Q000276:immunology*; D003228:Conjunctiva / Q000276:immunology; D004847:Epithelial Cells / Q000276:immunology; D005260:Female; D007249:Inflammation; D016023:Integrins / Q000302:isolation & purification; D007413:Intestinal Mucosa / Q000276:immunology; D008565:Membrane Proteins; D051379:Mice; D008810:Mice, Inbred C57BL; D009092:Mucous Membrane / Q000276:immunology*; D020545:Respiratory Mucosa / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D014566:Urogenital System / Q000276:immunology
D000954:Antigens, Surface; D015815:Cell Adhesion Molecules; D016023:Integrins; C069886:L-selectin counter-receptors; D008565:Membrane Proteins